“Bimekizumab 3-Year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-Term Pooled Analysis from Five Phase 3 3b Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 1, Jan. 2024, p. s305, https://doi.org/10.25251/skin.8.supp.305.